Guided Therapeutics (GTHP) Long-Term Debt Issuances (2012 - 2025)

Guided Therapeutics has disclosed Long-Term Debt Issuances across 13 years of filings, most recently posting -$303000.0 for Q4 2025.

• Long-Term Debt Issuances for Q4 2025 came in at -$303000.0, down 27.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $160000.0 (up 113.33% YoY), and the FY2025 annual result was $160000.0, up 113.33% from the prior year.
• Long-Term Debt Issuances came in at -$303000.0 for Q4 2025 at Guided Therapeutics, down from $108000.0 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $1.4 million in Q3 2022 to a low of -$1.4 million in Q4 2022.
• The 4-year median for Long-Term Debt Issuances is $131000.0 (2024), against an average of $43900.0.
• Across the five-year window, Long-Term Debt Issuances soared 584.31% in 2022 and slipped 27.85% in 2025, its largest moves.
• Guided Therapeutics' Long-Term Debt Issuances stood at $204000.0 in 2021, then plunged by 784.31% to -$1.4 million in 2022, then soared by 83.02% to -$237000.0 in 2024, then declined by 27.85% to -$303000.0 in 2025.
• The last three Long-Term Debt Issuances figures came in at -$303000.0 (Q4 2025), $108000.0 (Q3 2025), and $150000.0 (Q2 2025), per Business Quant data.